GET DAILY SIGNALSWhy Is Axon Enterprise (AXON) Stock Down -17.33% Today?
Key Takeaways
- AXON shares fell 17.33% to $316.26, down from the prior session's close of $382.56.
- The selloff follows a third-quarter earnings miss and a cut to full-year revenue guidance driven by delays in federal Dedrone counter-drone deployments.
- Secondary pressure came from a lowered free-cash-flow outlook and a capital-intensive $1.2 billion investment raising Axon's stake in drone maker Skydio to 37%.
- The decline is company-specific: the Nasdaq and S&P 500 both traded higher, underscoring that weakness was not driven by the broader market.
- A wave of analyst price-target cuts and at least one downgrade amplified selling pressure.
- Traders are watching whether delayed federal deployments close later, along with Q4 execution and margin trends.
- For more detail, explore Price Targets, Earnings, and Forecast pages for AXON.
- Discover actionable trading ideas by exploring Trending AI Robots.
Opening Summary
Axon Enterprise, Inc. (AXON), a public-safety technology company best known for TASER conducted-energy devices, body cameras, and cloud-based digital evidence and software platforms, saw its stock tumble 17.33% on Thursday, with shares trading near $316.26 versus a prior close of $382.56. The sharp decline extended a selloff that began after the company reported third-quarter results that missed Wall Street estimates and reduced its full-year revenue outlook, citing slower-than-expected federal procurement cycles for counter-drone deployments.
Earnings Miss and Guidance Cut
The primary catalyst was a disappointing third-quarter report. Revenue rose 28% year over year to a record $908.55 million, but that figure fell short of the consensus estimate of roughly $935 million to $940 million. Non-GAAP earnings of $1.72 per share also missed expectations of about $1.88 to $1.91. While software and services revenue accelerated 43% to $437 million, the headline top-line shortfall was tied to a roughly $30 million federal Dedrone deployment that did not close during the quarter.
More damaging was management's decision to lower full-year revenue guidance to a range of $3.610 billion to $3.630 billion, down from $3.670 billion to $3.725 billion. The revision reflects approximately $130 million in federal Dedrone deployments no longer expected to land in 2026 because of slower government procurement cycles. Fourth-quarter revenue guidance of $990 million to $1.01 billion also came in below the Street's roughly $1.06 billion estimate, while the free-cash-flow target was trimmed to $350 million to $400 million from about $450 million.
Skydio Investment and Capital Allocation Concerns
Alongside results, Axon announced an additional $1.2 billion investment in drone maker Skydio, lifting its ownership stake to 37% and securing exclusive public-safety distribution rights in the U.S. and Canada. While management framed the move as a strategic bet on "Drone as First Responder" technology, investors weighed the significant capital commitment at a time when margins were already under pressure. Adjusted gross margin fell to 59.2% from 62.7% a year earlier, reflecting a heavier mix of counter-drone hardware, higher memory costs, and new product scaling.
Analyst Reactions and Market Context
The earnings-driven move was reinforced by a wave of analyst revisions. Needham maintained a Buy rating but slashed its price target to $500 from $750, while Piper Sandler and Baird also lowered their targets. At least one research firm downgraded the stock from a strong-buy equivalent to a hold. The selling occurred against a backdrop of modest gains in the Nasdaq and S&P 500, confirming that the pressure on AXON was idiosyncratic rather than a reflection of broad market weakness. Trading volume was sharply elevated relative to the stock's typical activity, indicating heavy institutional repositioning after the report.
What Comes Next for AXON
Investors will be watching whether the delayed federal Dedrone deployments ultimately close, which could restore some of the removed revenue, and whether software momentum continues to offset lumpiness in the hardware-heavy counter-drone business. Attention will also focus on the execution of the Skydio investment and its impact on cash flow and margins. Risks include continued unpredictability in federal procurement timing, margin compression from memory costs and product mix, and elevated valuation multiples that leave limited room for further stumbles.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots, drawn from hundreds of bots that track thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Traders looking to navigate volatile moves like today's can explore these tools to identify potential opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AXON in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Indicator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 37 cases over the following month. The odds of a continued upward trend are 76%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 57 cases where AXON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 56 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.458) is normal, around the industry mean (4.689). AXON has a moderately high P/E Ratio (154.883) as compared to the industry average of (17.589). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement